'Mad Money' Uncovered: Big Pharma on a Down Day in the Market

TheStreet.com

NEW YORK (TheStreet) -- Jim Cramer likes the growth-oriented as well as the yield-oriented Big Pharma stocks, he told Nicole Urken, "Mad Money's" research associate, Monday. "The international investor who is looking for a home will want to find yield and will want to find safety."

One thing the big-cap pharma companies have done is to return money to shareholders, Cramer said. "They're all about bringing out values. Pfizer Pfizer has done a series of gigantic moves to bring out value."

He said the takeaway for a Merck or a Johnson & Johnson is all very clear, he said. These companies make a lot of money and they have good balance sheets and they continue to return capital. "So, they've become banks for foreigners."

He added, These groups are a better safe haven than any other group in the market."

"Pharma isn't what it was a decade ago," Urken agreed. "Keep it on your radar. In this kind of a market it's a group that continues to work."

To sign up for Jim Cramer's free Booyah! newsletter, with all of his latest articles and videos, please click here.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

Rates

View Comments (0)